Microcirculation In Acute Coronary Syndromes

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this mechanistic pilot study in 40 patients the investigators will compare the findings in patients treated with very early high dose statin therapy with historic controls from the KOMPIS study published in EHJ 200925. The investigators want to assess if early high dose statin therapy in patients treated with primary PCI:

1. reduces area of myocardial infarction, reduces volumes and improves remodelling as assessed by MRI at 2 days and at 2 months

2. improves microcirculation (Decreased number of patients with MO) as assessed by first pass time estimated with MRI 2 days

3. have impact on coronary blood flow as assessed by intravascular registrations and TIMI frame count immediately after PCI

4. reduce levels of CK-MB and TnT measured as area under the curve during the hospital stay at improves neurohumoral profile assessed by Heart Rate Variability (HRV) and neurohormones at discharge and at 2 months follow-up

5. improves endothelial function assessed by flow mediated vasodilatation at discharge

6. alters Peak VO2 at 1 and 6 month

7. reduce levels of CRP and pro-inflammatory cytokines during index hospitalization and at follow-up alters collagen turnover

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Helse Stavanger HF
• Collaborators: Helse Vest; St. Olavs Hospital; University Hospital of North Norway
• Treatments: Rosuvastatin Calcium; Simvastatin

Criteria

Inclusion Criteria:

• Age > 18 years

• Evidence of acute ST elevation myocardial infarct.

• Planned primary PCI procedure.

• Obtained written informed consent.

• "One vessel disease"

Exclusion Criteria:

• History of previous myocardial infarction

• History of valvular disease

• Ongoing therapy for hyperlipidemia

• History of heart failure

• Any active non-cardiac co-morbidity or condition that is likely to compromise patient cooperation or survival during the follow-up period of the study.

• Pregnancy (In doubt a urine test will be employed before treatment)

• Lactating females

• Asians

• Previous muscle disease

• Reduced glomerular filtration

• Active hepatic disease

• Ongoing oral anticoagulation therapy

• Ongoing cyclosporine therapy